Adaptive Biotechnologies Corp (NASDAQ:ADPT) has a beta value of 1.55 and has seen 0.71 million shares traded in the recent trading session. The company, currently valued at $1.24B, closed the recent trade at $8.41 per share which meant it gained $0.14 on the day or 1.69% during that session. The ADPT stock price is -6.42% off its 52-week high price of $8.95 and 72.89% above the 52-week low of $2.28.
The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is Hold stock at the moment, with a recommendation rating of 1.50. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 11 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.29.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Sporting 1.69% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADPT stock price touched $8.41 or saw a rise of 6.03%. Year-to-date, Adaptive Biotechnologies Corp shares have moved 40.28%, while the 5-day performance has seen it change 7.82%. Over the past 30 days, the shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) have changed 23.49%.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 39.93% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $18.0. In that case, then, we find that the latest price level in today’s session is -114.03% off the targeted high while a plunge would see the stock lose 40.55% from the levels at last check today.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
The company’s shares have gained 74.11% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 18.33%.
6 analysts offering their estimates for the company have set an average revenue estimate of 44.08M for the current quarter. 6 have an estimated revenue figure of 48.56M for the next ending quarter. Year-ago sales stood 41.87M and 43.19M respectively for this quarter and the next, and analysts expect sales will grow by 5.26% for the current quarter and 18.33% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.51% over the past 5 years. Earnings growth for 2025 is a modest 13.09% while over the next 5 years, the company’s earnings are expected to increase by 27.30%.
ADPT Dividends
Adaptive Biotechnologies Corp is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 29.99 million shares worth more than $108.58 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 20.3466% of shares outstanding.
The other major institutional holder is RUBRIC CAPITAL MANAGEMENT LP, with the holding of over 14.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $50.68 million and represent 9.4971% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 6.30% shares in the company for having 9.3 shares of worth $80.15 million while later fund manager owns 4.19 shares of worth $36.13 million as of Sep 30, 2024, which makes it owner of about 2.84% of company’s outstanding stock.
